-
Obravnava anemije pri bolnikih s srčnim popuščanjem = Treatment of anemia in heart failure patientsŠebeštjen, Miran ; Keber, Irena ; Jug, Borut, 1975-The prevalence of anemia in patients with advanced heart failure is significant and is present in more than 50 % of this patient population. The exact pathophysiologic mechanism of anemia in heart ... failure is still not known- it could be a direct consequence of the heart failure or it could be caused by some other disease in this population of polymorbid patients. There are several mechanisms through which heart failure could contribute to the development of anemia. The most plausible among them are hemodilution, renal insuffi ciency, increased proinflammatory cytokines, malnutrition, decreased erhythropoiesis in bone marrow and heart-failure medications (predominantly ACEI). Anemia is an independant risk factor for recurrent hospitalizations andincreased mortality. Several small-scale studies demonstrated that the treatment of anemia in heart-failure patients decreased heart failure signs and symptoms in this patient population. Anemia in heart-failure patients can be treated with: blood transfusion, iron replacement therapy, or with synthetic analogues of erhythropoietin. Before the treatment with synthetic analogues of erhythropoietin. is started, other causes of anemia (gastrointestinal bleeding, malnutrition, renal insuffi ciency, hematological diseases and malignancies) have to be excluded. Iron blood levels, ferritin, transferrin and TIBC also have to be determined. If body iron stores are depleted, iron has to be replaced intravenously, the target levels of ferritinbeing around 250 ng/mL. If anemia persists after 2 weeks of iron replacement therapy, treatment with erhythropoietin is indicated. Currently 4 erhythropoietin analogues are available: epoetin alpha (EprexR), epoetin beta (NeoRecormon R), darbepoetin alpha (AranespR) and metoksipolietilenglikol epoetin beta (MirceraR). Anemia needs to be treated in all NYHA III and IV heart failure patients and hemoglobin levels below 110 g/dL. (Abstract truncated at 2000 characters)Vir: Zdravniški vestnik : glasilo Slovenskega zdravniškega društva = Slovenian medical journal = journal of Slovenian Medical Association. - ISSN 1318-0347 (Letn. 79, št. 2, feb. 2010, str. 134-145)Vrsta gradiva - članek, sestavni delLeto - 2010Jezik - slovenskiCOBISS.SI-ID - 26739929
Avtor
Šebeštjen, Miran |
Keber, Irena |
Jug, Borut, 1975-
Teme
Heart Failure, Congestive |
Anemia |
Erythropoietin |
Iron |
Erythrocyte Transfusion |
Treatment Outcome |
Anemija |
Železo |
Eritrocitna transfuzija |
Srce, odpoved kongestivna |
Eritropoietin |
Zdravljenje, izid |
anemija |
srčno popuščanje |
zdravljenje
vir: Zdravniški vestnik : glasilo Slovenskega zdravniškega društva = Slovenian medical journal = journal of Slovenian Medical Association. - ISSN 1318-0347 (Letn. 79, št. 2, feb. 2010, str. 134-145)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|---|
Šebeštjen, Miran | 19345 |
Keber, Irena | 00365 |
Jug, Borut, 1975- | 24467 |
Izberite prevzemno mesto:
Prevzem gradiva po pošti
Obvestilo
Gesla v Splošnem geslovniku COBISS
Izbira mesta prevzema
Mesto prevzema | Status gradiva | Rezervacija |
---|
Prosimo, počakajte trenutek.
Naročanje gradiva za izposojo v čitalnice
Naročanje kopij člankov
Urnik dostave gradiva z oznako DS v signaturi